Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

Matthew Saunders¹, Sophie Comyn¹, Borka Medjo¹, Zahra Anderson¹, Chase LaCombe¹, Jake Ripley¹, Kyra Chapman¹, Tim Ma¹, Abigail Ventura¹, Alyssa Ruelos¹, Alec Jaeger¹, Chase Poindexter¹, Ophelia Rebanal¹, Nemanja Vuvic¹, Sean M West¹, David Eavarone¹, John M Sutton², Douglas Ganini da Silva¹, David A Spencer²

¹Biologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.

²AI Research and Engineering, Absci Corporation, Vancouver, WA, USA.

PubMed PMC DOI PDF

Abstract

Antibody polyreactivity, which is characterized by broad, low-affinity off-target binding, is an undesirable drug property associated with rapid clearance. Existing in vitro screening methods often suffer from interassay variability, while current in silico models lack the generalizability needed to efficiently identify non-polyreactive variants within the localized sequence spaces typical of drug…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.